Results 11 to 20 of about 4,363 (145)

Evaluation of In vivo Bioactivity of a Mutated Streptokinase [PDF]

Novelty in Biomedicine, 2017
 Background: Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination of the amino acid residues that are responsible for immunogenicity while don’t affect the bioactivity of streptokinase is worthy. Recently, we
Marzieh Sameni, Mazaher Gholipourmalekabadi, Mojgan Bandehpour, Mehrdad Hashemi, Farzin Sahebjam, V Tohidi, Bahram Kazemi   +6 more
doaj   +2 more sources

Side Effects of Intravenous Streptokinase in Different Age Groups Patients with Acute Myocardial Infarction

Armaghane Danesh Bimonthly Journal, 2014
Background & aim: Myocardial infarction is one of the most common cardiovascular diseases. Streptokinase is used in patients with myocardial infarction with ST-segment elevation.
M Behnam Moghadam, R Zeighami, J Azimian, H Jahanihashemi, M Fotuhi   +4 more
doaj   +1 more source

STREPTOKINASE EFFICACY IN MYOCARDIAL INFARCTION MANAGEMENT: IS IT RELATED TO SERUM ANTISTREPTOKINASE ANTIBODY TITER

Journal of Research in Medical Sciences, 2000
Introduction. Antistreptokinase antibodies in sera of individuals with previous streptococcal infection might theoretically influence the thrombolytic activity of streptokinase. Streptokinase as the only thrombolytic drug is used in MI management in Iran.
H SHEMIRANI, A REZAEI, S MATIN KHAH, F OREYZI   +3 more
doaj   +1 more source

Fibrinolytic Activity of Recombinant Mutant Streptokinase [PDF]

Novelty in Biomedicine, 2015
Background: Streptokinase is a bacterial protein produced by different beta hemolytic streptococci and widely used in thrombolytic treatment. The main disadvantage of using streptokinase is antibody formation which causes allergic reaction to neutralize ...
Mahboobeh Mobarrez, Mojgan Bandehpour, Massoud Salehmoghadam, Bahram Kazemi   +3 more
doaj   +2 more sources

Transient acute renal failure after coronary thrombolysis with streptokinase [PDF]

Revista Cubana de Medicina Militar, 2021
Introduction: There are currently more than 150 medications related to the appearance of rhabdomyolysis and transient acute renal failure. Streptokinase can be one of them.
Rodolfo Vega Candelario, Junior Vega Jiménez   +1 more
doaj   +1 more source

Do high levels of antistreptokinase limit the efficacy of streptokinase in patients with myocardial infarction?

ARYA Atherosclerosis, 2012
BACKGROUND: Antistreptokinase antibody in serum of people who had been exposed to streptococcal infections may interfere with thrombolytic effects of streptokinase.
Hassan Shemirani, Abbass Rezaie, Saeed Matinkhah, Farzad Arizi   +3 more
doaj   +1 more source

Immunoglobulin Attenuates Streptokinase-Mediated Virulence inStreptococcus dysgalactiae Subspeciesequisimilis Necrotizing Fasciitis [PDF]

, 2021
A clinicalStreptococcus dysgalactiae equisimilis strain secreting high levels of streptokinase promoted severe disease in a patient lacking anti-streptokinase antibodies.
Marques Maggio, Ewerton, Andreoni, Federica, Ugolini, Fabio, Keller, Nadia, Hollands, Andrew, Neff, Andrina, Zinkernagel, Annelies S., Schuepbach, Reto A., Nizet, Victor   +8 more
core  

Cloning and expression of truncated and intact streptokinase molecules in E.coli and evaluation of their biological activities [PDF]

مجله بیوتکنولوژی کشاورزی, 2010
Streptokinase is the most utilized drug for thrombolytic therapy. However, due to its nonhuman origin and nonspecific activity in the absence of fibrin, its application may encounter side effects such as allergic reactions and hemorrhage respectively. It
Reza Arabi, farzin Roohvand, Daryoosh Noroozian, MohMMdreza AghSADEGHI, Arash Memarnajadian, Hossin khan ahmad, Mehdi Sadat, Fatemah Motavalli   +7 more
doaj   +1 more source

Purification and characterization of recombinant Streptokinase expressed in E.coli from Streptococcus equisimilis with N-terminal methionine

Jurnal Teknologi Laboratorium, 2019
Streptokinase is a extracellular enzyme which is extracted from strains of beta Hemolytic streptococcus. The enzyme is a non-protease plasminogen activator that activates plasminogen to plasmin and degrades fibrin clot through its specific lysine binding
Pavan Kumar Vadla, Murali Tummuru, Dinesh Kumar   +2 more
doaj   +1 more source

Do recipients of kidneys from donors treated with streptokinase develop anti-streptokinase antibodies?

Streptokinase is used for preflush for non-heart-beating donors (NHBDs) in our center. The aim of this study was to evaluate whether the use of thrombolytic streptokinase results in the production of anti-streptokinase antibodies in the recipients after ...
Mi H, Gupta A, Soomro NA, Gok MA, Shenton BK, Carter V, Stamp S, Manas DM, Asher JF, Del Rio Martin J, Jaques BC, Talbot D   +11 more
core   +4 more sources